MedTrace Logo

Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest)

NCT02414854 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1902

Last updated 2018-10-23

Study results available
· View outcomes & findings →

Summary

Primary Objective:

To evaluate the efficacy of dupilumab (SAR231893 / REGN668) in participants with persistent asthma.

Secondary Objectives:

* To evaluate the safety and tolerability of dupilumab.
* To evaluate the effect of dupilumab on improving participant-reported outcomes including health-related quality of life.
* To evaluate dupilumab systemic exposure and incidence of anti-drug antibodies.

Conditions

Interventions

DRUG

Dupilumab

Solution for injection, Subcutaneous injection in the abdomen, upper thigh or upper arm.

DRUG

Placebo

Solution for injection, Subcutaneous injection in the abdomen, upper thigh or upper arm.

DRUG

Inhaled corticosteroid (ICS) therapy

Oral inhalation, stable dose (medium or high dose) of ICS in combination with up to 2 other controller medicines (second or third controller therapy)

DRUG

Albuterol/Salbutamol

Oral inhalation as needed

DRUG

Levalbuterol/Levosalbutamol

Oral inhalation as needed

Sponsors & Collaborators

Principal Investigators

  • Clinical Sciences & Operations · Sanofi

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-27
Primary Completion
2017-07-29
Completion
2017-11-23

Countries

  • United States
  • Argentina
  • Australia
  • Brazil
  • Canada
  • Chile
  • Colombia
  • France
  • Germany
  • Hungary
  • Italy
  • Japan
  • Mexico
  • Poland
  • Russia
  • South Africa
  • South Korea
  • Spain
  • Taiwan
  • Turkey (Türkiye)
  • Ukraine
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02414854 on ClinicalTrials.gov